Riociguat (Adempas®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001095
English
Authors' recommendations:
Riociguat (Adempas®) is recommended for use within NHS Wales for the treatment of adult patients with WHO functional class II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH); or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1608
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Enzyme Activators
- Adult
- Hypertension, Pulmonary
- Pyrazoles
- Pyrimidines
- Exercise
- Pulmonary Arterial Hypertension
- Soluble Guanylyl Cyclase
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.